SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Nov. 14, 2005--FibroGen, Inc., today announced that advances in the development of FG-2216 for the treatment of anemia and FG-4592, a pioneering therapy for the anemia of chronic disease (ACD), were reported at the American Society of Nephrology (ASN) 38th Annual Meeting & Scientific Exposition, November 8-13, Philadelphia, Pennsylvania.
